Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | Director | June 05, 2025 | June 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date June 05, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-06-05 | Direct | 35,144 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 35,144 · Balance 35,144 F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2025 Filed Jun 6, 2025 20:25 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 35,144 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000905148-25-002030 · form4.xml · derivative · entry 1 Elling Christian E · CIK 0001891306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,144 Underlying: Common Stock · 35,144 shares Expires 2035-06-05 F1 · derivative.exercise_date: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:14 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 45,642 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0000905148-24-001683 · form4.xml · derivative · entry 1 Elling Christian E · CIK 0001891306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,642 Underlying: Common Stock · 45,642 shares Expires 2034-06-06 F1 · derivative.exercise_date: These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| August 09, 2023 Filed Aug 12, 2023 01:24 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantWarrants (Right to Buy) · Derivative | 7,901,234 | $0.13 Strike: $2.47 | $987,654.25 |
DisclosureSEC source: 0001140361-23-039346 · form4.xml · derivative · entry 2 Elling Christian E · CIK 0001891306 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 7,901,234 Underlying: Common Stock · 7,901,234 shares Expires not disclosed F2 · derivative.expiration_date: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023). F1 · ownership.nature: The securities are held of record by Lundbeckfond Invest A/S. The Reporting Person is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S. The Reporting Person disclaims beneficial ownership of the securities held by Lundbeckfond Invest A/S except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 09, 2023 Filed Aug 12, 2023 01:24 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantCommon Stock | 7,901,234 | $1.90 | $15,012,344.60 |
DisclosureSEC source: 0001140361-23-039346 · form4.xml · nonDerivative · entry 1 Elling Christian E · CIK 0001891306 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 13,950,686 F1 · ownership.nature: The securities are held of record by Lundbeckfond Invest A/S. The Reporting Person is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S. The Reporting Person disclaims beneficial ownership of the securities held by Lundbeckfond Invest A/S except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 23:54 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 41,533 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-029694 · form4.xml · derivative · entry 1 Elling Christian E · CIK 0001891306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,533 Underlying: Common Stock · 41,533 shares Expires 2033-06-08 F1 · derivative.exercise_date: These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| May 26, 2022 Filed May 31, 2022 23:36 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 23,885 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001567619-22-011960 · doc1.xml · derivative · entry 1 Elling Christian E · CIK 0001891306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,885 Underlying: Common Stock · 23,885 shares Expires 2032-05-26 F1 · derivative.exercise_date: These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.